Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immatics NV (NQ: IMTX )

9.780 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.780
Bid (Size) 3.920 (2)
Ask (Size) 15.64 (2)
Prev. Close 9.780
Today's Range 9.780 - 9.780
52wk Range 6.460 - 13.16
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
-8.77%
-8.77%
1 Month
-13.98%
-13.98%
3 Month
-16.62%
-16.62%
6 Month
+25.38%
+25.38%
1 Year
+48.18%
+48.18%

More News

Read More
Immatics Announces Full Year 2023 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Immatics Shares Are Rising Today
Via Benzinga
Recap: Immatics Q1 Earnings
Via Benzinga
Why Immatics Stock Is Soaring Today
Via The Motley Fool
Immatics Announces Pricing of $175 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
From https://immatics.com/
Via GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
From https://immatics.com/
Via GlobeNewswire
Top 5 Health Care Stocks That May Crash This Month
Via Benzinga
Immatics Announces First Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
What's Going On With Immatics Shares Today
Via Benzinga
US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT Concerns
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.